Cancer Summaries and Commentaries™: Recent Advances in the Treatment of Gynecological Cancers: What we Learned in Barcelona

Release Date: November 27, 2019
Expiration Date: November 27, 2020
Media: Internet - based

Activity Overview

This online activity is designed to update physicians on data presented at the EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY Annual Meeting, held in September 2019 in Barcelona, Spain. Cancer Summaries and Commentaries™: Recent Advances in the Treatment of Gynecological Cancers: What we Learned in Barcelona online continuing medical education (CME) activity facilitates critical assessment and clinical integration of new evidence, when appropriate. The activity reviews 9 abstracts with some of the most compelling and clinically relevant gynecological (GYN) cancer presentations from the meeting. For each abstract, a short summary of key clinical data is accompanied by expert perspectives that provide insight into how clinicians can apply these findings to their clinical practice to improve patient care.

Benefits of Participating

• Hear from the experts about recent clinical trials in the field of GYN malignancies and their impact on clinical practice decisions
• Identify opportunities to implement emerging treatments for the management of endometrial, cervical, and ovarian cancer
• Explore the role of biomarkers in the treatment and management of GYN malignancies

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Merck & Co, Inc., and TESARO, A GSK Company.

Target Audience

This educational activity is directed toward medical oncologists and fellows who treat patients with gynecologic malignancies. Gynecologic oncologists, surgical oncologists, radiation oncologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment and management of patients with gynecologic malignancies are invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Outline methods that allow for optimized characterization of tumor biology among patients with gynecologic malignancies
• Explain the study design, rationale, and results of recent clinical trials evaluating novel strategies for the treatment of gynecologic malignancies
• Consider recent evidence in the context of evolving treatment paradigms in the field of gynecologic malignancies

Faculty, Staff, and Planners’ Disclosures

Faculty

Susana M. Campos, MD, MPH, MS
Assistant Professor of Medicine
Educational Director
Harvard Medical School
Boston, MA

Disclosures: Advisory: Tesaro, Eisai.

Alexandra Leary, MD, PhD
Medical Oncologist, Department of Medicine
Lab Leader, Gynecological Tumor Translational Research
Gustave Roussy Cancer Center
Paris, France

Disclosures: Grant/Research Support: Ability, Agenus, AstraZeneca, Bristol-Myers Squibb, Clovis Oncology, GamaMabs Pharma, Inivata, Iovance Biotherapeutics, Merus, MSD, PharmaMar, Roche, Sanofi. Consultant: Ability, AstraZeneca, Biocad, Clovis Oncology, GamaMabs, Merck Serono, MSD, Seattle Genetics, Tesaro.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER^® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER^® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a COI.

Additionally, PER^® is required by ACCME to resolve all COI. PER^® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or the company that provided commercial support.